ADARx Pharmaceuticals (ADRX) vs Palvella Therapeutics (PVLA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Palvella Therapeutics is the larger company by market cap ($1.95 billion vs $1.85 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADRX | PVLA |
|---|---|---|
| Share price | $17.28 | $135.40 |
| Market cap | $1.85B | $1.95B |
| 1-day change | -2.23% | +3.09% |
| YTD return | — | +25.48% |
| 1-year return | — | +75.47% |
| 5-year return | — | -63.60% |
| EPS (TTM) | $-1.16 | $-4.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-41.72M |
| 52-week high | $23.21 | $161.38 |
| 52-week low | $16.64 | $65.93 |
| Distance from 52-week high | -25.55% | -16.10% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +70.26% |
| Average volume | 1.25M | 211.36K |
| Shares outstanding | 106.80M | 14.41M |
| Employees | 100 | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About ADARx Pharmaceuticals
ADRX stock →ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Palvella Therapeutics
PVLA stock →Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
ADRX vs PVLA FAQ
Which is bigger, ADARx Pharmaceuticals or Palvella Therapeutics?
Palvella Therapeutics (PVLA) is larger, with a market capitalization of $1.95B compared with $1.85B for ADARx Pharmaceuticals (ADRX).
Are ADARx Pharmaceuticals and Palvella Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.